

Securities Market Commission
Att. Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 29 October 2024

In accordance with article 227 of Law 6/2023, of 17 March, on the Securities Markets and Investment Services (*Ley 6/2023, de 17 de marzo, de los Mercados de Valores y de los Servicios de Inversión*), and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

In connection with the shares buy-back program announced by way of a communication of other relevant information dated 30 April 2024 (registration number 28,360) and following our communication of other relevant information dated 26 September 2024 (registration number 30,638), the Board of Directors of Pharma Mar, S.A. (the "**Company**") has agreed, at its meeting held today, to implement the share capital reduction through the redemption of treasury shares agreed by the Company's General Shareholders' Meeting held on 29 May 2024, at second call, under the fourth resolution on the agenda.

The Company's share capital has been reduced by EUR 79,607.40, through the redemption of 132,679 own shares held by the Company as treasury stock, with a nominal value of EUR 0.60 each. The share capital resulting from this reduction has been set at EUR 10,933,336.80, divided into 18,222,228 shares with a nominal value of EUR 0.60 each.

The purpose of the share capital reduction is to redeem the Company's treasury shares, thereby improving the profit per share and contributing to shareholder remuneration. The share capital reduction has not involved the return of contributions to shareholders, as the Company itself is the owner of the redeemed shares.

The share capital reduction has been carried out against free reserves, through the allocation of a reserve for an amount equal to the nominal value of the redeemed shares (i.e. EUR 79,607.40), which can only be used with the same formalities as those required for the reduction of share capital, pursuant to article 335.c) of the Spanish Companies Act (*Real Decreto Legislativo 1/2010, de 2 de julio, por el que se aprueba el texto refundido de la Ley de Sociedades de Capital*). Consequently, the Company's creditors do not have the right of opposition referred to in article 334 of the Spanish Companies Act in relation to the share capital reduction.

The mandatory announcements of the share capital reduction will be published on the Company's corporate website (www.pharmamar.com) and in the Official Commercial Registry Bulletin on 31 October 2024.

The Company will proceed to execute the corresponding public deed of share capital reduction and amendment of the Company's Bylaws and to register it in the Madrid Commercial Registry, and once it has been recorded in the Company's register sheet opened in the Commercial Registry, the Company will determine the date on which the aforementioned share capital reduction will take effect.

Likewise, the Company shall proceed to request the delisting of the shares that have been redeemed from the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges, on which the stock is listed, through the Spanish Stock Exchange Interconnection System (Continuous Market).